Disclaimer¶

For purposes of this Disclaimer, the “Service” means the Molecular Oncology Almanac database, software, API, browsers, and related materials.

THIS DATABASE AND SOFTWARE HAVE NOT BEEN VALIDATED FOR DIAGNOSTIC OR CLINICAL USE, AND DANA-FARBER CANCER INSTITUTE (DFCI) MAKES NO WARRANTY OF FITNESS FOR DIAGNOSTIC OR CLINICAL USE. USERS ARE SOLELY RESPONSIBLE FOR ENSURING THAT THEIR ACCESS TO AND USE OF THE DATABASE, SOFTWARE, API, BROWSERS, AND RELATED MATERIALS COMPLIES WITH ALL APPLICABLE LAWS, REGULATIONS, INSTITUTIONAL POLICIES, AND ETHICAL REQUIREMENTS, INCLUDING ANY REQUIREMENTS APPLICABLE TO RESEARCH INVOLVING HUMAN SUBJECTS OR HUMAN-DERIVED DATA. DFCI MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT OR VALIDITY OF ANY INTELLECTUAL PROPERTY RIGHTS OR CLAIMS, WHETHER ISSUED OR PENDING, AND THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE.

In no event shall DFCI or its trustees, directors, officers, employees, students, affiliates, core faculty, associate faculty and contractors be liable for incidental, punitive, consequential or special damages, including economic damages or injury to persons or property or lost profits, regardless of whether the party was advised, had other reason to know or in fact knew of the possibility of the foregoing, regardless of fault, and regardless of legal theory or basis. To the extent liability cannot be disclaimed, DFCI’s liability shall be limited to direct, actual damages resulting from DFCI’s failure to perform its obligations under the applicable terms.

The Molecular Oncology Almanac database is made available under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, including commercial use, provided appropriate credit is given. The software is licensed under the GNU General Public License, Version 2 (GPL v2). Certain third-party code or materials may be subject to separate license terms. For additional terms governing access to and use of the Service, please see the Terms of use.